News and Publications

November 28, 2023

A 5-minute, low-cost molecular diagnostic testing solution for infectious diseases

Prominex, San Diego, California

• We have developed an ultrafast molecular diagnostic testing solution for infectious diseases that delivers lab-quality results in as little as 5 minutes at a cost comparable to that of rapid antigen tests. With our easy assay workflow, we can directly process crude clinical specimens, without sample preparation, simplifying and expediting time to result.
• Our approach combines a novel molecular nuclease-based amplification technology (dCliP) with the simplicity of a digital lateral flow detection technology. Our dCliP system is capable of simultaneously detecting the presence of different infectious agents such as SARS-CoV-2 and Influenza for respiratory diseases and Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) for STIs.
• Our reusable digital device is easy-to-use and eliminates user interpretation of results addressing current accessibility issues for individuals with disabilities.

February 24, 2020

Funding development of 5-minute point-of-care molecular diagnostics . Prominex, Inc., a molecular diagnostic company focused on point-of-care infectious disease testing, today announces completion of its Series B-1 financing, raising $8 million from Casdin Capital LLC.

May 31, 2019

Funding development of 5-minute point-of-care molecular diagnostics . Prominex, Inc., a molecular diagnostic company focused on point-of-care infectious disease testing, today announces completion of its Series B financing, raising $6 million from Casdin Capital LLC and Paul Thomas, its founding CEO.

September 26, 2018

NEW YORK (GenomeWeb) – With novel amplification and detection technology, startup Prominex promises fully-automated multiplex molecular point-of-care testing that can provide results in five minutes.

September 13, 2018

Funding development of 5-minute point-of-care molecular diagnostics . Prominex, Inc., a molecular diagnostic company focused on point-of-care infectious disease testing, today announces completion of its Series A-1 financing, raising $4 million from Casdin Capital LLC and Paul Thomas, its founding CEO.